About me
Eamonn is a strategic communications and investor relations leader with extensive experience across the pharmaceutical, biotech and healthcare non-profit sectors. He specializes in advising C-Suite leadership, building corporate reputation, promoting a company’s value proposition and developing innovative programming to outperform business objectives.
Eamonn is currently Senior Director of Corporate Communications and Investor Relations at MorphoSys, a global biotechnology company focused on the development and commercialization of innovative cancer medicines. In this role, he leads corporate, digital, social media, financial and CEO communications. Notably, he has overseen the first rebranding of the company’s strategy and image in over 30 years, the release of positive Phase 3 results for the company’s lead asset pelabresib and the announcement of a successful capital raise.
Prior to MorphoSys, Eamonn was a member of Pfizer’s Global Media Relations team, acting as a media spokesperson for the company’s commercial organization spanning six therapeutic areas and more than 500 medicines. Eamonn played a pivotal role in driving news coverage of the Pfizer-BioNTech COVID-19 vaccine, establishing relationships and placing exclusive stories in The Wall Street Journal, The New York Times, USA TODAY, and The Washington Post and many others. Before that, Eamonn managed corporate and internal communications for Pfizer's oncology division, product communications for Pfizer’s breast and prostate cancer franchises, and global and U.S. cancer patient programming.
Eamonn has also worked for two top-tier communications agencies, dna Communications (part of the IPG network) and Ruder Finn, where he drove award-winning programming across multiple client accounts including the Boehringer Ingelheim/Eli Lilly and Company alliance, Celgene (a BMS Company) and Novartis.
Eamonn is a graduate of Providence College and currently resides in New York, NY. He volunteers with Habitat for Humanity and Big Brothers & Big Sisters of America.
